A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors

INTRODUCTION: Emicizumab is a recombinant humanized bispecific monoclonal antibody mimicking the cofactor function of activated factor VIII. AIM: In this multicentre, open‐label study (HOHOEMI), we evaluated the efficacy, safety and pharmacokinetics of emicizumab in Japanese paediatric patients aged...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Haemophilia
Päätekijät: Shima, Midori, Nogami, Keiji, Nagami, Sayaka, Yoshida, Seitaro, Yoneyama, Koichiro, Ishiguro, Akira, Suzuki, Takashi, Taki, Masashi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6900083/
https://ncbi.nlm.nih.gov/pubmed/31515851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.13848
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia